Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

Nxera Pharma reported strong Q2 2026 results with revenue of JPY 18.9 billion, up from the prior year, driven by eight R&D milestone events. The company achieved key regulatory designations for vamorolone in South Korea, progressed partnered programs with Neurocrine, Lilly, and AbbVie, and benefited from Lilly's acquisition of Centessa Pharmaceuticals. Operating profit turned positive at JPY 1.9 billion versus a prior loss, with core operating profit reaching JPY 6.5 billion.